Equities Analysts Issue Forecasts for Zentalis Pharmaceuticals, Inc.’s FY2024 Earnings (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – Analysts at Wedbush lifted their FY2024 earnings per share (EPS) estimates for shares of Zentalis Pharmaceuticals in a research report issued to clients and investors on Tuesday, June 18th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($2.31) per share for the year, up from their prior forecast of ($2.33). Wedbush currently has a “Underperform” rating and a $4.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.72) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals’ Q4 2024 earnings at ($0.69) EPS, Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.73) EPS, Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($2.78) EPS, FY2026 earnings at ($2.46) EPS, FY2027 earnings at ($2.02) EPS and FY2028 earnings at ($1.26) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Tuesday, May 7th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.91. The company had revenue of $40.56 million during the quarter, compared to analysts’ expectations of $35.00 million. During the same period in the prior year, the company posted ($1.07) earnings per share.

Several other brokerages also recently issued reports on ZNTL. Oppenheimer cut their price target on shares of Zentalis Pharmaceuticals from $50.00 to $25.00 and set an “outperform” rating on the stock in a report on Tuesday. HC Wainwright cut their target price on Zentalis Pharmaceuticals from $40.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday. Stifel Nicolaus decreased their price target on Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating for the company in a research note on Tuesday. Jefferies Financial Group reaffirmed a “hold” rating and set a $6.00 price objective (down from $42.00) on shares of Zentalis Pharmaceuticals in a research report on Tuesday. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $8.00 target price (down previously from $38.00) on shares of Zentalis Pharmaceuticals in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, Zentalis Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $11.33.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock opened at $5.25 on Friday. The company has a market capitalization of $372.91 million, a price-to-earnings ratio of -1.58 and a beta of 1.83. Zentalis Pharmaceuticals has a one year low of $3.93 and a one year high of $30.53. The company’s 50-day moving average is $11.16 and its 200 day moving average is $12.97.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other news, insider Diana Hausman sold 3,356 shares of the business’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $12.62, for a total transaction of $42,352.72. Following the completion of the sale, the insider now owns 373,876 shares of the company’s stock, valued at approximately $4,718,315.12. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, insider Diana Hausman sold 3,356 shares of Zentalis Pharmaceuticals stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $12.62, for a total transaction of $42,352.72. Following the transaction, the insider now directly owns 373,876 shares of the company’s stock, valued at approximately $4,718,315.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Cam Gallagher sold 9,597 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $11.98, for a total transaction of $114,972.06. Following the transaction, the chief financial officer now directly owns 633,680 shares in the company, valued at approximately $7,591,486.40. The disclosure for this sale can be found here. 6.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Large investors have recently made changes to their positions in the business. Quest Partners LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter worth about $38,000. Tower Research Capital LLC TRC grew its holdings in Zentalis Pharmaceuticals by 252.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock valued at $55,000 after buying an additional 2,589 shares in the last quarter. Exchange Traded Concepts LLC raised its position in shares of Zentalis Pharmaceuticals by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 5,989 shares of the company’s stock valued at $91,000 after buying an additional 1,519 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Zentalis Pharmaceuticals by 352.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,188 shares of the company’s stock worth $124,000 after buying an additional 6,379 shares in the last quarter. Finally, OneAscent Financial Services LLC bought a new position in shares of Zentalis Pharmaceuticals during the fourth quarter worth $156,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.